We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+7.58%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$2.41B
AUM Growth
-$3.75B
Cap. Flow
-$4.09B
Cap. Flow %
-169.35%
Top 10 Hldgs %
31.78%
Holding
6,989
New
537
Increased
1,703
Reduced
3,620
Closed
686

Sector Composition

Rank Sector Weight
1 Technology 21.71%
2 Healthcare 7.7%
3 Consumer Discretionary 6.83%
4 Financials 6.52%
5 Industrials 4.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PMVP icon
1801
PMV Pharmaceuticals
PMVP
$69.3M
$105K ﹤0.01%
12,092
-12,602
-51% -$134K
SEIC icon
1802
SEI Investments
SEIC
$12.6B
$105K ﹤0.01%
1,797
-2,331
-56% -$131K
TLRY icon
1803
Tilray
TLRY
$651M
$105K ﹤0.01%
3,852
-196
-5% -$6.87K
ALLO icon
1804
Allogene Therapeutics
ALLO
$732M
$104K ﹤0.01%
16,454
-10,824
-40% -$100K
ASTE icon
1805
Astec Industries
ASTE
$989M
$104K ﹤0.01%
2,562
+595
+30% +$24K
HCM icon
1806
HUTCHMED
HCM
$2.17B
$104K ﹤0.01%
7,076
-22,641
-76% -$248K
HELE icon
1807
Helen of Troy
HELE
$682M
$104K ﹤0.01%
936
-3,168
-77% -$308K
MZZ icon
1808
ProShares UltraShort MidCap400
MZZ
$2.35M
$104K ﹤0.01%
6,095
-407
-6% -$7.14K
SCHD icon
1809
Schwab US Dividend Equity ETF
SCHD
$107B
$104K ﹤0.01%
+4,146
New +$102K
SCPH
1810
DELISTED
scPharmaceuticals
SCPH
$104K ﹤0.01%
14,449
+6,433
+80% +$39.3K
SXT icon
1811
Sensient Technologies
SXT
$5.61B
$104K ﹤0.01%
1,417
-2,838
-67% -$203K
JOYY
1812
JOYY Inc
JOYY
$3.7B
$104K ﹤0.01%
3,308
-395
-11% -$11.4K
OIIM
1813
DELISTED
02Micro International
OIIM
$104K ﹤0.01%
23,216
-110
-0.5% -$477
ABR icon
1814
Arbor Realty Trust
ABR
$998M
$103K ﹤0.01%
7,766
-12,714
-62% -$173K
BCBP icon
1815
BCB Bancorp
BCBP
$158M
$103K ﹤0.01%
5,684
+1,448
+34% +$27.1K
BG icon
1816
Bunge Global
BG
$21.4B
$103K ﹤0.01%
1,033
-6,712
-87% -$645K
BMBL icon
1817
Bumble
BMBL
$367M
$103K ﹤0.01%
4,897
-573
-10% -$13.2K
DFUS
1818
Dimensional US Equity ETF
DFUS
$21.6B
$103K ﹤0.01%
2,473
-4,294
-63% -$180K
GLBE icon
1819
Global E Online
GLBE
$6.86B
$103K ﹤0.01%
5,009
+1,801
+56% +$40.9K
IRT icon
1820
Independence Realty Trust
IRT
$3.93B
$103K ﹤0.01%
6,122
-16,885
-73% -$286K
R icon
1821
Ryder
R
$9.92B
$103K ﹤0.01%
1,233
-1,144
-48% -$96K
RUN icon
1822
Sunrun
RUN
$2.42B
$103K ﹤0.01%
4,304
-33,756
-89% -$901K
WEN icon
1823
Wendy's
WEN
$1.44B
$103K ﹤0.01%
4,557
-4,645
-50% -$99.2K
AXGN icon
1824
Axogen
AXGN
$2.61B
$102K ﹤0.01%
10,212
+1,303
+15% +$14.5K
ENVX icon
1825
Enovix
ENVX
$1.05B
$102K ﹤0.01%
9,362
-58,435
-86% -$719K

Similar funds

Tower Research Capital (TRC)'s Q4 2022 Portfolio in Review

As of Q4 2022, Tower Research Capital (TRC) held 6,989 positions worth $2.41B, down 61% from $6.16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tower Research Capital (TRC) withdrew a net $4.09B in Q4 2022, closing 686 positions and reducing 3,620 holdings. Its most notable exit was Vanguard Russell 2000 Value ETF, an estimated $4.46M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Tower Research Capital (TRC) opened a new position in iShares Semiconductor ETF worth $9.33M.

  • Tower Research Capital (TRC)'s largest Q4 2022 buy was iShares Semiconductor ETF: 80,454 shares worth $9.33M.
  • Tower Research Capital (TRC) added most to iShares Russell 2000 ETF in Q4 2022, an estimated $145M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2022 reduction was Apple, cutting an estimated $322M.
  • Tower Research Capital (TRC) fully exited Vanguard Russell 2000 Value ETF in Q4 2022, selling an estimated $4.46M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 32% of its $2.41B portfolio in Q4 2022.
  • Tower Research Capital (TRC) opened 537 new positions and closed 686 in Q4 2022.
  • Tower Research Capital (TRC)'s portfolio value fell 61% quarter-over-quarter to $2.41B.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.